{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:42:24Z","timestamp":1792813344545,"version":"4.5.0"},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020948","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recurrent hyperkalaemia (HK) is associated with increased morbidity and mortality, and is common among patients with cardiorenal disease. Many of these patients require renin\u2013angiotensin\u2013aldosterone system inhibitor (RAASi) therapies that further enhance the risk of HK. Every acute HK episode constitutes an opportunity to treat and prevent recurrent HK. This report aims to support multidisciplinary team efforts in managing patients who may be affected by recurrent HK. A panel of nine European experts in the management of HK (four nephrologists, four cardiologists, one internist) reviewed existing guidance and evidence on the diagnosis and management of HK at a face-to-face (26th September 2023) and two virtual meetings (24th January and 14th March 2024). The panel developed 10 consensus recommendations and a management algorithm across three domains: duty of care, identifying patients at risk of HK recurrence and managing the risk of HK recurrence. Early identification and management of those at risk of recurrent HK will improve clinical outcomes but requires an interdisciplinary, co-ordinated approach. Disease-modifying therapies such as RAASi should no longer be considered reversible causes of HK, and efforts should be taken to up-titrate these to guideline-directed target doses even in the setting of an acute HK event. Every acute HK episode constitutes an opportunity to treat and prevent recurrent HK, contributing to long-term clinical benefits. The recommendations, intentionally broad in scope, complement existing management guidelines and plans, fostering a collective responsibility among healthcare professionals managing patients with HK.<\/jats:p>","DOI":"10.1093\/ehjcvp\/pvaf055","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:18:48Z","timestamp":1752837528000},"page":"630-637","source":"Crossref","is-referenced-by-count":5,"title":["Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7732-0887","authenticated-orcid":false,"given":"Gianluigi","family":"Savarese","sequence":"first","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset ; Karolinska Institutet, Sjukhusbacken 10, 11883 Stockholm \u00a0","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario de Burgos , Burgos 09006 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Bonanad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario de Valencia , Valencia 46010 ,","place":["Spain"]},{"name":"Instituto de Investigacion Sanitaria INCLIVA , Valencia 46010 ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4701-7227","authenticated-orcid":false,"given":"Aaron","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Princess of Wales Hospital , Bridgend CF31 1RQ ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University Hospital Schleswig-Holstein , Kiel 24105 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Nephrology, Universit\u00e0 degli Studi di Verona , Verona 37126 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Dentali","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, Medical Center, Ospedale di Circolo & Fondazione Macchi , ASST Sette Laghi 21100, Varese ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O","family":"Burton","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Sciences, University of Leicester , Leicester LE1 7RH ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4023-2263","authenticated-orcid":false,"given":"Giuseppe","family":"Rosano","sequence":"additional","affiliation":[{"name":"Department of Human Sciences and Promotion of Quality of Life, Chair of Pharmacology, San Raffaele University of Rome , Rome 00166 ,","place":["Italy"]},{"name":"Center of Clinical and Experimental Medicine, IRCCS San Raffaele , Roma 20132 ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"2026020411182632100_pvaf055-B1","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","article-title":"Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes","volume":"46","author":"Collins","year":"2017","journal-title":"Am J Nephrol"},{"key":"2026020411182632100_pvaf055-B2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.ekir.2021.02.038","article-title":"Hyperkalemia and its association with mortality, cardiovascular events, hospitalizations, and intensive care unit admissions in a population-based retrospective cohort","volume":"6","author":"Hougen","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026020411182632100_pvaf055-B3","doi-asserted-by":"crossref","first-page":"e13941","DOI":"10.1111\/ijcp.13941","article-title":"Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions","volume":"75","author":"Tafesse","year":"2021","journal-title":"Int J Clin Pract"},{"key":"2026020411182632100_pvaf055-B4","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1186\/cc11872","article-title":"Severe hyperkalemia requiring hospitalization: predictors of mortality","volume":"16","author":"An","year":"2012","journal-title":"Crit Care"},{"key":"2026020411182632100_pvaf055-B5","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/ndt\/gfx312","article-title":"Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study","volume":"33","author":"Thomsen","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2026020411182632100_pvaf055-B6","doi-asserted-by":"crossref","first-page":"e008912","DOI":"10.1161\/JAHA.118.008912","article-title":"Elevated potassium levels in patients with congestive heart failure: occurrence, risk factors, and clinical outcomes: a Danish population-based cohort study","volume":"7","author":"Thomsen","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2026020411182632100_pvaf055-B7","doi-asserted-by":"crossref","first-page":"e012655","DOI":"10.1161\/JAHA.119.012655","article-title":"Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom","volume":"8","author":"Linde","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"2026020411182632100_pvaf055-B8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12882-022-03054-5","article-title":"Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia","volume":"24","author":"Kanda","year":"2023","journal-title":"BMC Nephrol"},{"key":"2026020411182632100_pvaf055-B9","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1093\/ndt\/gfae016","article-title":"Hyperkalaemia-related reduction of RAASi treatment associates with more subsequent inpatient care","volume":"39","author":"Svensson","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026020411182632100_pvaf055-B10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","article-title":"Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology","volume":"4","author":"Rosano","year":"2018","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2026020411182632100_pvaf055-B11","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2024","journal-title":"Kidney Int"},{"key":"2026020411182632100_pvaf055-B12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1253\/circj.CJ-24-0844","article-title":"Establishing cross-specialty expert consensus on the optimal management of hyperkalemia in patients with heart failure and chronic kidney disease","volume":"89","author":"Kitai","year":"2025","journal-title":"Circ J"},{"key":"2026020411182632100_pvaf055-B13","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1002\/nop2.1607","article-title":"Fragmented care and chronic illness patient outcomes: a systematic review","volume":"10","author":"Joo","year":"2023","journal-title":"Nurs Open"},{"key":"2026020411182632100_pvaf055-B14","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"2026020411182632100_pvaf055-B15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11739-023-03427-0","article-title":"Recommendations for the management of hyperkalemia in patients receiving renin-angiotensin-aldosterone system inhibitors","volume":"19","author":"De Nicola","year":"2024","journal-title":"Intern Emerg Med"},{"key":"2026020411182632100_pvaf055-B16","volume-title":"Clinical Practice Guidelines: Treatment of Acute Hyperkalaemia in Adults","author":"Alfonzo","year":"2022"},{"key":"2026020411182632100_pvaf055-B17","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"2026020411182632100_pvaf055-B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cardfail.2025.07.008","article-title":"JCS\/JHFS 2025 guideline on diagnosis and treatment of heart failure","author":"Kitai","year":"2025","journal-title":"J Card Fail"},{"key":"2026020411182632100_pvaf055-B19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.kint.2019.09.018","article-title":"Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO). Controversies Conference","volume":"97","author":"Clase","year":"2020","journal-title":"Kidney Int"},{"key":"2026020411182632100_pvaf055-B20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ehjqcco\/qcaa069","article-title":"European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes","volume":"8","author":"Aktaa","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2026020411182632100_pvaf055-B21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2026020411182632100_pvaf055-B22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2020","journal-title":"Kidney Int"},{"key":"2026020411182632100_pvaf055-B23","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026020411182632100_pvaf055-B24","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026020411182632100_pvaf055-B25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/MEJ.0000000000000691","article-title":"Acute hyperkalemia in the emergency department: a summary from a kidney disease: improving global outcomes conference","volume":"27","author":"Lindner","year":"2020","journal-title":"Eur J Emerg Med"},{"key":"2026020411182632100_pvaf055-B26","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1002\/ehf2.12796","article-title":"Management and outcomes of heart failure patients with CKD: experience from an inter-disciplinary clinic","volume":"7","author":"Nguyen","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2026020411182632100_pvaf055-B27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cardfail.2023.09.002","article-title":"Safety indicators in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial","volume":"30","author":"Tomasoni","year":"2024","journal-title":"J Card Fail"},{"key":"2026020411182632100_pvaf055-B28","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","article-title":"Real-world modifications of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE I study","volume":"40","author":"Agiro","year":"2023","journal-title":"Adv Ther"},{"key":"2026020411182632100_pvaf055-B29","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","article-title":"Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2026020411182632100_pvaf055-B30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1410853","article-title":"Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors","volume":"372","author":"Weir","year":"2015","journal-title":"N Engl J Med"},{"key":"2026020411182632100_pvaf055-B31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","article-title":"Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure","volume":"85","author":"Kosiborod","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026020411182632100_pvaf055-B32","volume-title":"StatPearls [Internet]","author":"Simon"},{"key":"2026020411182632100_pvaf055-B33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/HCO.0000000000000709","article-title":"Hyperkalemia in heart failure","volume":"35","author":"Sidhu","year":"2020","journal-title":"Curr Opin Cardiol"},{"key":"2026020411182632100_pvaf055-B34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4239\/wjd.v7.i5.101","article-title":"Hyporeninemic hypoaldosteronism and diabetes mellitus: pathophysiology assumptions, clinical aspects and implications for management","volume":"7","author":"Sousa","year":"2016","journal-title":"World J Diabetes"},{"key":"2026020411182632100_pvaf055-B35","doi-asserted-by":"crossref","first-page":"7372","DOI":"10.3402\/jchimp.v1i4.7372","article-title":"Treatment and pathogenesis of acute hyperkalemia","volume":"1","author":"Mushiyakh","year":"2012","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"2026020411182632100_pvaf055-B36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12882-019-1250-0","article-title":"Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England","volume":"20","author":"Horne","year":"2019","journal-title":"BMC Nephrol"},{"key":"2026020411182632100_pvaf055-B37","doi-asserted-by":"crossref","first-page":"e0218739","DOI":"10.1371\/journal.pone.0218739","article-title":"Predictors for repeated hyperkalemia and potassium trajectories in high-risk patients\u2014a population-based cohort study","volume":"14","author":"Adelborg","year":"2019","journal-title":"PLoS One"},{"key":"2026020411182632100_pvaf055-B38","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s12325-021-02017-w","article-title":"Real-world management of hyperkalemia in the emergency department: an electronic medical record analysis","volume":"39","author":"Davis","year":"2022","journal-title":"Adv Ther"},{"key":"2026020411182632100_pvaf055-B39","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/gfae056","article-title":"Hyperkalemia treatment standard","volume":"39","author":"Palmer","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"2026020411182632100_pvaf055-B40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"2026020411182632100_pvaf055-B41","doi-asserted-by":"crossref","first-page":"e12572","DOI":"10.1002\/emp2.12572","article-title":"Hyperkalemia management in the emergency department: an expert panel consensus","volume":"2","author":"Rafique","year":"2021","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"2026020411182632100_pvaf055-B42","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.xkme.2020.04.007","article-title":"Impact of dietary potassium restrictions in CKD on clinical outcomes: benefits of a plant-based diet","volume":"2","author":"Clegg","year":"2020","journal-title":"Kidney Med"},{"key":"2026020411182632100_pvaf055-B43","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2026020411182632100_pvaf055-B44","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1159\/000504078","article-title":"Efficacy and safety of sodium zirconium cyclosilicate for treatment of hyperkalemia: an 11-month open-label extension of HARMONIZE","volume":"50","author":"Roger","year":"2019","journal-title":"Am J Nephrol"},{"key":"2026020411182632100_pvaf055-B45","author":"National Institute for Health and Care Excellence"},{"key":"2026020411182632100_pvaf055-B46","author":"National Institute for Health and Care Excellence"},{"key":"2026020411182632100_pvaf055-B47","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ekir.2020.02.1028","article-title":"Current management of hyperkalemia in patients on dialysis","volume":"5","author":"Bansal","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026020411182632100_pvaf055-B48","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2026020411182632100_pvaf055-B49","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1002\/ejhf.2287","article-title":"Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care","volume":"23","author":"Trevisan","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026020411182632100_pvaf055-B50","author":"Rastogi"},{"key":"2026020411182632100_pvaf055-B51","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"2026020411182632100_pvaf055-B52","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ehf2.14268","article-title":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure","volume":"10","author":"Tardif","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026020411182632100_pvaf055-B53","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2026020411182632100_pvaf055-B54","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ajme.2012.07.003","article-title":"Awareness of hypertension guidelines among family physicians in primary health care","volume":"49","author":"Al-Ali","year":"2013","journal-title":"Alexandria J Med"},{"key":"2026020411182632100_pvaf055-B55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5830\/CVJA-2016-048","article-title":"Awareness of hypertension guidelines and the diagnosis and evaluation of hypertension by primary care physicians in Nigeria","volume":"28","author":"Ale","year":"2017","journal-title":"Cardiovasc J Afr"},{"key":"2026020411182632100_pvaf055-B56","doi-asserted-by":"crossref","first-page":"e012818","DOI":"10.1136\/bmjopen-2016-012818","article-title":"Adherence to guidelines for creatinine and potassium monitoring and discontinuation following renin\u2013angiotensin system blockade: a UK general practice-based cohort study","volume":"7","author":"Schmidt","year":"2017","journal-title":"BMJ Open"},{"key":"2026020411182632100_pvaf055-B57","first-page":"16","article-title":"Laboratory monitoring to reduce adverse drug-related events: a mixed methods study","volume":"28","author":"Harrison","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2026020411182632100_pvaf055-B58","doi-asserted-by":"crossref","first-page":"e007682","DOI":"10.1161\/CIRCOUTCOMES.120.007682","article-title":"Cardiometabolic center of excellence: a novel care delivery model for secondary prevention of cardiovascular disease in type 2 diabetes","volume":"14","author":"Thomas","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026020411182632100_pvaf055-B59","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jama.2023.2854","article-title":"Coordinated care to optimize cardiovascular preventive therapies in type 2 diabetes: a randomized clinical trial","volume":"329","author":"Pagidipati","year":"2023","journal-title":"JAMA"},{"key":"2026020411182632100_pvaf055-B60","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1111\/dom.15485","article-title":"Inter-relationships between cardiovascular, renal and metabolic diseases: underlying evidence and implications for integrated interdisciplinary care and management","volume":"26","author":"Vora","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"2026020411182632100_pvaf055-B61","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaf055\/63807749\/pvaf055.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/7\/630\/63807749\/pvaf055.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/11\/7\/630\/63807749\/pvaf055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T16:18:39Z","timestamp":1770221919000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/11\/7\/630\/8209442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":61,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7,21]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaf055","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,7,21]]}}}